FDA's Small Dispenser Survey Explained

LSPedia Welcomes the Survey

FDA has released its Small Dispensers Assessment Survey, the data-gathering step it committed to under the Drug Supply Chain Security Act before deciding how, and for whom, to enforce the law's interoperable, electronic, package-level tracing requirements. LSPedia welcomes this survey. It is the mechanism that lets FDA move from assumption to evidence: instead of guessing at what compliance costs a 3-location independent pharmacy versus a 200-location chain, the agency will have real numbers, in the respondents' own words, before it decides what enforcement discretion should look like past the current milestone.

This matters because the alternative, enforcement policy set without asking the people it affects, tends to produce blanket rules that are either too lenient for supply chain security or too rigid for a pharmacy running on a skeleton staff. A survey grounded in operational and financial reality is a better foundation than either extreme.

‍

‍

What the Survey Is

The survey (OMB Control No. 0910-0937) is built around six sections. It opens by confirming who is answering, a small dispenser directly, defined as 25 or fewer full-time employees, or an organization completing it on that dispenser's behalf. From there it moves through the dispenser's demographic profile, locations, prescription volume, revenue, staffing, and services offered; the current state of DSCSA data exchange, paper versus electronic; a detailed accounting of paper-based transaction errors, how often they occur, what causes them, and how many calendar days and personnel hours it takes to resolve each one; and finally, two forward-looking sections on the cost, feasibility, and operational impact of moving to full interoperable electronic tracing, including a direct question on whether the dispenser expects to be fully compliant by November 27, 2027.

In plain terms: FDA is asking small dispensers to show their work. What does non-compliance actually cost them today, in paper handling and reconciliation time? What would compliance cost them tomorrow, in software, hardware, and staff? And where, specifically, would meeting the requirement create genuine hardship rather than routine inconvenience? That level of specificity is what separates a defensible enforcement policy from a guess.

‍

‍

What It Really Takes to Answer FDA’s Small Dispenser Survey

For most independent pharmacies at this size, there's no dedicated compliance or IT role, so it falls to the pharmacist-in-charge/owner, or, if the pharmacy has one, an office/operations manager who already handles purchasing and vendor relationships. That's the person who knows locations, prescription volume, revenue, staffing, and services offered (Section 2), and who's dealt with wholesale distributors directly enough to speak to current data exchange practices and future software/hardware readiness (Sections 3, 5, 6).

Section 4 is the exception, the paper-error questions (order counts, discrepancy counts, days to resolve, personnel-hours per discrepancy) aren't things anyone carries in their head. Answering them accurately means pulling actual receiving records, invoices, or discrepancy logs, which in a small pharmacy is usually whoever handles receiving day to day (often a senior technician), not the owner.

On time: the demographic and forward-looking questions (Sections 2, 3, 5, 6) are answerable from knowledge in maybe 30 minutes total. Section 4 is the bottleneck, if the pharmacy already tracks discrepancies somewhere, tallying 12 months of data might take another 60 minutes; if they don't, which is common at this scale, it could mean digging through paper invoices for hours, or giving FDA a rough estimate rather than a hard count.  

So realistically: half a day for someone with decent records, easily a full day if they have to reconstruct the paper-error numbers by hand, which is itself a small, ironic proof of the survey's point about paper-based burden.

‍

‍

Small Dispenser Options

Dispensers reading this survey have three practical paths forward, and they are not mutually exclusive.  

The first is to build or maintain DSCSA interoperability in-house, feasible for larger independents with IT support, but for most small dispensers this is where the survey's own cost and personnel-time questions become uncomfortably real.  

The second is to adopt a turnkey, vendor-managed platform designed specifically for this scale of operation, one that has an established network with wholesalers and manufacturers and plugs into existing pharmacy management systems and marketplaces rather than asking the pharmacy to become a systems integrator.

The third is to use the survey itself, and any subsequent hardship or discretion request, as the vehicle to document a specific dispenser's circumstances, whether those circumstances point to resource constraints, a DSCSA system implementation plan, or a future WEER application. Small Dispenser Solution: LSPedia Pharmacy Pro

Completing FDA’s survey may take a half day to a full day. In that same amount of time, a small dispenser can begin implementing LSPedia Pharmacy Pro, a turnkey DSCSA compliance solution that moves the pharmacy from paper into the digital age. Starting at just a few dollars a day, Pharmacy Pro can help save an estimated 90 minutes a day, reduce manual compliance work, and ease the workload for already-stressed pharmacy staff.

‍

What Small Dispensers Are Seeing in Practice

Small dispenser experiences are already showing why this transition is not just a compliance exercise. When the right workflow is in place, DSCSA readiness can reduce daily friction instead of adding to it.

The practical takeaway is simple: the survey should not be treated only as a regulatory burden. It is also a decision point. A dispenser that answers honestly and specifically, with real order counts, real discrepancy time, and real cost estimates, gives themselves a clearer basis for deciding whether to build internally, adopt a turnkey digital workflow, or document a specific need for relief.

‍

‍

Likely Impact to Dispensers and Their Trading Partners

For dispensers, the near-term impact is administrative before it is technological: the real burden documented in this survey, hours per week spent chasing down a mismatched shipment or a missing lot number, doesn't go away on its own, and it scales with prescription volume, not with FTE count. That is precisely why a blanket extension is the wrong instrument. It protects the 3-location independent pharmacy running lean, but it equally protects operations that have simply deferred a manageable investment. Only dispenser-specific data, of the kind this survey collects, can tell the difference.

For wholesale distributors (WDDs), a slower-than-planned small dispenser transition means continuing to support dual paper-and-electronic workflows longer than budgeted, and continuing to absorb the reconciliation cost when a paper-based transaction doesn't match the physical product. For manufacturers (MAHs), it means extended exposure on the return and verification side: product moving through the chain with incomplete or non-electronic traceability data is harder to authenticate, harder to trace back to the source of a discrepancy, and more likely to generate a return or investigation that a fully electronic trading partner would have resolved automatically. Both WDDs and MAHs have a direct commercial interest in seeing small dispensers get to full compliance, not in seeing the deadline pushed out again with no differentiation.

‍

‍

Impact on the US Drug Supply Chain's Fight Against Counterfeit and Diversion

This is where the stakes go beyond administrative convenience. Interoperable, electronic, package-level tracing exists because it is the mechanism that lets a suspect or illegitimate product be identified and quarantined before it reaches a patient. Every dispenser still operating on paper, or on partial electronic exchange, is a point in the chain where that verification loop is weaker, not because the dispenser is doing anything wrong, but because the infrastructure around them hasn't caught up. A supply chain is only as secure as its least-connected node, and small dispensers, simply by volume, represent a large share of those nodes.

A blanket, industry-wide extension of enforcement discretion, applied the same way to every small dispenser regardless of actual readiness, treats all of those nodes as equally low-risk, which they are not. Some are one turnkey vendor relationship away from full compliance; others face a genuine, documentable hardship. Conditioning enforcement discretion on the individual pharmacy's actual, surveyed circumstances, rather than extending it uniformly, is the only approach that closes the gap for dispensers who need real relief without leaving a wide, undifferentiated opening in the counterfeit and diversion defense that DSCSA was written to build. That is LSPedia's position, and it is the outcome this survey, done honestly, is positioned to support.

‍

LSPedia helps dispensers of every size meet DSCSA's interoperable tracing requirements without adding headcount. For a walkthrough of what a turnkey path to compliance looks like for your pharmacy, reach out to your LSPedia representative.